Page 25 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Expanded access program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Expanded Access Program Today - Breaking & Trending Today

FDA Approves Hepzato Kit for Metastatic Uveal Melanoma

The Hepzato Kit is a direct-to-liver therapy for patients with uveal melanoma with hepatic metastases. ....

Vojislav Vukovic , Access Program , Drug Administration , National Comprehensive Cancer Network , Hepzato Kit , Delcath Systems , Expanded Access Program , Risk Evaluation , Mitigation Strategy , Uveal Melanoma ,

Delcath Systems Stock Soars 90% In One Session - Here's Why - Delcath Systems (NASDAQ:DCTH)

The FDA approved Delcath Systems Inc's (NASDAQ: DCTH) HEPZATO KIT (melphalan/Hepatic Delivery System).  ....

Delcath Systems Inc , Access Program , Hepatic Delivery System , Expanded Access Program , Public Equity ,

Seelos Therapeutics Provides Second Quarter 2023 Clinical Update

- Seelos expects to release top-line data in its registration directed study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation . ....

United States , New York , Anthony Marciano , Mike Moyer , Los Angeles , Lifesci Advisors , Harvard Medical School At Massachusetts , Society For Neuroscience , Nasdaq Hearings Panel , Prnewswire Seelos Therapeutics Inc , Seelos Therapeutics Inc , Access Program , Nasdaq Stock Market , Exchange Commission , American Society Of Gene , National Institute Of Neurological Disorders , Intranasal Racemic Ketamine , Acute Suicidal Ideation , Major Depressive Disorder , Nasdaq Listing Rule , Expanded Access Program , National Institute , Neurological Disorders , Accelerating Access , Critical Therapies , Harvard Medical School ,

Clarity's theranostic prostate cancer trial advances to highest dose level

Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been. ....

New South Wales , United States , Alan Taylor , Luke Nordquist , Safety Review Committee , Technology Platform , Urology Cancer Center Xcancer Omaha , Clarity Pharmaceuticals , American Cancer Institute , Drug Administration , Prnewswire Clarity Pharmaceuticals , Access Program , Prostate Specific Antigen , United States Food , Expanded Access Program , Prostate Specific Membrane Antigen , Urologic Medical Oncologist , Principal Investigator , Urology Cancer Center , Executive Chairperson , Targeted Copper Theranostic , Health Care Amp Hospitals , Medical Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,

Clarity's theranostic prostate cancer trial advances to highest dose level

Clarity's theranostic prostate cancer trial advances to highest dose level
sydneysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sydneysun.com Daily Mail and Mail on Sunday newspapers.

United States , New South Wales , Luke Nordquist , Alan Taylor , Urology Cancer Center Xcancer Omaha , Technology Platform , Safety Review Committee , Prnewswire Clarity Pharmaceuticals , Access Program , Clarity Pharmaceuticals , American Cancer Institute , Drug Administration , Prostate Specific Antigen , United States Food , Expanded Access Program , Prostate Specific Membrane Antigen , Urologic Medical Oncologist , Principal Investigator , Urology Cancer Center , Executive Chairperson , Targeted Copper Theranostic ,